Ensign Peak Advisors
ARCT icon

Ensign Peak Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Ensign Peak Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26,680
Closed -$395K – 1809
2022
Q3 		$395K Sell
26,680
-9,940
-27% -$167K ﹤0.01% 1577
2022
Q2 		$576K Buy
36,620
+29,580
+420% +$580K ﹤0.01% 1392
2022
Q1 		$190K Hold
7,040
– – ﹤0.01% 1887
2021
Q4 		$261K Buy
+7,040
New +$287K ﹤0.01% 1857

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ensign Peak Advisors's ARCT Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Arcturus Therapeutics (ARCT) in Q4 2022, closing a stake of 26,680 shares — an estimated $395K sold.

Ensign Peak Advisors first reported a position in ARCT in Q4 2021 and held it in 4 quarters. The position peaked at $576K in Q2 2022. 111 funds tracked by Wall St. Rank hold ARCT as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Arcturus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 26,680 Arcturus Therapeutics shares in Q4 2022, an estimated $395K.
  • Ensign Peak Advisors first reported a position in Arcturus Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Arcturus Therapeutics position peaked at $576K in Q2 2022.
  • 111 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.